Moxifloxacin Stulln (Moxifloxacin)

Moxifloxacin works by binding to bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and replication. Inhibiting these enzymes stops bacterial DNA synthesis, leading to rapid bacterial cell death and resolution of the infection.

The dosing regimen for Moxifloxacin Stulln is determined by the prescribing clinician based on the severity of the infection, patient age, and response to therapy. Typical regimens involve one to two drops per eye at specified intervals, but the exact schedule must be provided by a qualified eye‑care professional.

Safety data for ocular moxifloxacin during pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Moxifloxacin offers a broader spectrum of activity and higher potency against many ocular pathogens compared with older fluoroquinolones such as ciprofloxacin. It also provides good penetration into corneal tissue, allowing effective treatment of both superficial and deeper infections, while maintaining a convenient dosing schedule.

Store the ophthalmic solution below 25 °C in its original container, protecting it from light and moisture. Keep the bottle tightly closed when not in use and discard any product that appears discolored or contains particles.

Moxifloxacin Stulln is applied as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid to create a pocket, and instill the prescribed number of drops. The eye should be gently closed for a few seconds to allow absorption, avoiding blinking or rubbing.

Serious risks, although rare, include corneal ulceration or worsening of existing corneal lesions, severe allergic reactions such as anaphylaxis, and systemic tendon injury. Patients should be instructed to seek immediate medical attention if they experience worsening eye pain, vision changes, or signs of a systemic allergic response.

Individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation should avoid using the product. It is also contraindicated in patients with active corneal epithelial defects unless specifically directed by an eye‑care specialist.